Neurodegenerative Diseases Drugs Market Size to Hit US$ 85.0 Bn by 2032: Persistence Market Research

The neurodegenerative diseases drugs market is undergoing transformative growth, propelled by advanced therapies, regulatory shifts, and a rapidly aging global population. With a projected market valuation of US$ 85.0 Bn by 2032, up from US$ 58.4 Bn in 2025, the sector is expected to grow at a CAGR of 5.5% during the forecast period from 2025 to 2032. As demand increases for disease-modifying treatments over symptomatic relief, pharmaceutical innovators are racing to develop therapies for Alzheimer's, Parkinson's, multiple sclerosis (MS), and other neurodegenerative disorders.

According to Persistence Market Research, the most significant share of the market is captured by immunomodulators, thanks to their effectiveness in targeting neuroinflammatory pathways. North America remains the dominant region in 2025, holding an estimated 51.8% share, driven by policy support, reimbursement expansions, and advanced diagnostic infrastructure. Meanwhile, multiple sclerosis is the leading segment by disease indication, supported by high funding levels, accessible biomarkers, and effective drug pipelines.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35538

Key Highlights from the Report

• The market is projected to grow from US$ 58.4 Bn in 2025 to US$ 85.0 Bn by 2032.
• Immunomodulators are expected to account for nearly 43.5% market share in 2025.
• Multiple sclerosis remains the top disease segment due to a strong development pipeline.
• Shift from symptomatic treatment to biologics and immunotherapy is driving innovation.
• North America leads due to robust diagnostics, FDA approvals, and expanded reimbursements.
• Regulatory momentum and investment in biomarkers are reshaping early diagnosis.

Market Segmentation
Drug Class and Therapeutic Category

The drug class segmentation includes immunomodulators, interferons, decarboxylase inhibitors, dopamine agonists, and others. Immunomodulators are forecast to dominate with 43.5% of the market share in 2025, especially in diseases like multiple sclerosis that have a clear autoimmune basis. These drugs are also supported by regulatory momentum and strong clinical endpoints. Interferons, although earlier-generation treatments, remain vital in certain MS regimens due to their anti-inflammatory benefits.

Dopamine agonists are rapidly gaining ground in Parkinson's treatment strategies, increasingly being used to delay levodopa initiation and reduce long-term motor complications. These include drugs like pramipexole, ropinirole, and rotigotine, which are showing efficacy in early-stage disease management, especially when combined with advanced delivery systems.

Disease Indication and End-Use Segments

By disease indication, the neurodegenerative diseases drugs market is segmented into multiple sclerosis, Alzheimer's disease, Parkinson's disease, spinal muscular atrophy (SMA), and others. Among these, multiple sclerosis is projected to lead with over 62.6% share in 2025, largely due to its well-defined biomarkers and growing number of approved disease-modifying therapies.

Alzheimer's disease follows closely due to its high patient burden and growing global prevalence. It is the most researched indication due to rising political support, massive investment in drug trials, and the societal cost of caregiving. Furthermore, end-users such as hospitals, neurology clinics, and specialty centers are increasingly adopting combination therapy protocols to improve patient outcomes.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/neurodegenerative-disease-drugs-market.asp

Regional Insights
North America

North America, primarily driven by the United States, is poised to dominate the market, fueled by aggressive funding, early diagnosis efforts, and high regulatory approval rates. With the FDA's full approval of Leqembi (lecanemab) for early-stage Alzheimer's, and the CMS expanding coverage, both investors and care providers are accelerating drug rollout. Canada, while supportive, is more cost-conscious, limiting certain reimbursements.

Europe

In Europe, stringent health economics assessments influence market entry. Regulatory bodies such as the EMA and the German G-BA are cautious, often requiring long-term cost-effectiveness data. However, public-private partnerships under the Innovative Health Initiative (IHI) are funding cutting-edge neurodegenerative research. Countries like Germany, France, and the UK are investing in real-world data to evaluate therapeutic outcomes.

Market Drivers

The push toward early diagnosis is a primary growth catalyst. As new drugs like lecanemab and donanemab target preclinical or early-stage Alzheimer's, healthcare systems are ramping up diagnostics like PET scans, CSF biomarker assays, and blood-based tests. These innovations are expanding the treatable patient base and reinforcing demand for biomarker-guided therapies. As a result, pharmaceutical pipelines are realigning to develop treatments for prodromal and mild cognitive impairment stages.

Market Restraints

Despite approvals, diagnostic gaps and reimbursement biases are slowing real-world adoption of new therapies. Clinicians remain wary of drugs that require expensive diagnostic confirmation, such as amyloid PET scans or lumbar punctures for CSF analysis. Additionally, traditional reimbursement structures continue to favor low-cost symptomatic treatments like levodopa and donepezil, creating resistance to newer, higher-cost drugs without long-term data.

Market Opportunities

Stem cell therapies and gene-based approaches are opening new frontiers in the market. The launch of iPSC-based dopamine cell therapy trials for Parkinson's by BlueRock Therapeutics signals growing confidence in regenerative medicine. Drug developers are now exploring combination treatments where stem cells are supported by immunomodulators or anti-inflammatory agents to enhance engraftment and efficacy. This shift represents a move from maintenance therapies to potential cures.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35538

Reasons to Buy the Report

• Offers detailed market forecasts and segmentation through 2032.
• Includes strategic analysis of key players and late-stage clinical candidates.
• Provides insights into regulatory frameworks across major regions.
• Covers disruptive technologies like stem cell therapy and antisense drugs.
• Utilizes expert-verified statistics from Persistence Market Research.

Frequently Asked Questions (FAQs)

• How big is the neurodegenerative diseases drugs market expected to be by 2032?
• Who are the key players in the global market for neurodegenerative diseases drugs?
• What is the projected growth rate of the neurodegenerative diseases drugs market?
• What is the market forecast for neurodegenerative diseases drugs for 2032?
• Which region is estimated to dominate the industry through the forecast period?

Company Insights

Leading Companies Operating in the Market

• Biogen
• Pfizer, Inc.
• Hoffmann-La Roche Ltd.
• Merck & Co., Inc.
• Novartis AG
• Sanofi
• Teva Pharmaceutical Industries Ltd.
• Orion Pharma
• UCB S.A
• ACADIA Pharmaceuticals Inc.
• Lundbeck A/S
• Mitsubishi Tanabe Pharma Corporation
• Others

Recent Market Developments

• In July 2025, Klotho Neurosciences received FDA Orphan Drug Designation for its gene therapy KLTO-202 targeting ALS.
• In March 2025, Alpha Cognition Inc. launched ZUNVEYL, a new treatment for mild-to-moderate Alzheimer's disease, targeting accessible and cost-effective care solutions.

Conclusion

The neurodegenerative diseases drugs market is at a crucial juncture where innovations in biologics, diagnostics, and regenerative medicine are pushing boundaries. The market is evolving from a symptomatic treatment landscape to one focused on disease modification, early intervention, and personalized medicine. As pharmaceutical companies expand their pipelines, and public health bodies recognize the burden of conditions like Alzheimer's and Parkinson's, the demand for effective therapies is only set to rise.

Persistence Market Research's insights validate that biomarker-enabled diagnosis, immunomodulation, and patient stratification are the future pillars of this high-growth sector. Although reimbursement and diagnostic challenges persist, the industry is witnessing a paradigm shift toward precision neurology. With evolving drug classes, expanding indications, and global collaborations, stakeholders across the spectrum-from payers and providers to patients-stand to benefit in the years ahead.

Read More Related Reports:

Facial Aesthetics Market https://www.persistencemarketresearch.com/market-research/facial-aesthetics-market.asp
Medical And Industrial Gloves Market https://www.persistencemarketresearch.com/market-research/medical-and-industrial-gloves-market.asp
Home Care Services Market https://www.persistencemarketresearch.com/market-research/home-care-services-market.asp
Bone And Joint Health Supplements Market https://www.persistencemarketresearch.com/market-research/bone-and-joint-health-supplements-market.asp
Scoliosis Management Market https://www.persistencemarketresearch.com/market-research/scoliosis-management-market.asp
Lithotripsy Devices Market https://www.persistencemarketresearch.com/market-research/lithotripsy-devices-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.